all

The National Lipid Association (NLA) welcomes the results of the REVEAL trial which demonstrated that reductions in cholesterol levels with anacetrapib were associated with a reduction in cardiovascular events.  Specifically, cholesterol drug anacetrapib produced reductions in low density lipoprotein (LDL) cholesterol levels, non-high density lipoprotein (non-HDL) cholesterol levels, lipoprotein(a) levels and a profound increase in high density lipoprotein (HDL) cholesterol levels.  These favorable lipid changes were associated with a significant reduction in cardiovascular events

The American Board of Clinical Lipidology (ABCL) Board of Directors has published a list of recommended reading for those preparing for maintenance of certification (MOC). If you’re studying for the exam, you can find a list of suggested reading at lipidboard.org/moc.

As your new president I extend my warm greetings. 

Some introductions first.  I am a clinical pharmacist working for the Department of Veterans Affairs at Buffalo, New York.  My Lipid Clinic Practice is now 29-years-old, and I have been with NELA for over 15 of those years.  As part of my clinical practice, I am co-director of the National VA Clinical Pharmacy Task Group for anticoagulation management.